Court weighs mifepristone limits as 770-900 LA women use pills monthly

For healthcare and health IT audiences, the clinical stakes are immediate: mifepristone-based medication abortion is the most common method in the country, increasingly delivered through telehealth and mail-order channels that shield laws were designed to protect. Restrictions would force patients toward procedural care or self-managed abortion while forcing telehealth platforms to reassess prescribing workflows, licensure exposure, and pharmacy distribution. The FDA's safety review will determine whether national prescribing rules change through regulation rather than litigation.

A three-judge panel of the New Orleans-based 5th U.S. Circuit Court of Appeals heard oral arguments on Wednesday, September 9, 2026, over whether prescribing rules should be tightened for mifepristone, one of two drugs used in the most common abortion method in the United States. The case, brought by Louisiana Attorney General Liz Murrill and plaintiff Rosalie Markezich, is one of three moving through the federal courts as abortion opponents attempt to block providers in states where abortion remains legal from sending abortion pills into states where it is not.

“

abortions, roughly 60%, are now obtained using the two-drug combination of mifepristone and misoprostol.

The litigation unfolds four years after the Supreme Court's June 2022 Dobbs decision returned abortion regulation to the states. In that time, medication abortion has become the dominant method: at least 3 in 5 U.S. abortions, roughly 60%, are now obtained using the two-drug combination of mifepristone and misoprostol. That shift has collided with the growth of telehealth prescribing and the "shield laws" adopted by abortion-legal states to protect clinicians who prescribe to patients in ban states. A survey conducted for the Society of Family Planning estimates that between 770 and 900 Louisiana women obtained abortions each month in 2025 using pills prescribed online or by doctors or nurse practitioners in other states, a workaround that has frustrated anti-abortion advocates and now forms the factual backbone of the Louisiana challenge.

The legal stakes extend well beyond Louisiana. The core question is whether a ban state can reach across its borders to constrain out-of-state prescribers and disrupt a federally approved drug's national distribution. The U.S. Food and Drug Administration says it is reviewing the prescribing rules and could call for changes, and argues that its agency process should take precedence over court action, a primary-jurisdiction and preemption argument that echoes the post-Loper Bright era's unresolved questions about how much deference courts owe federal agencies. If the 5th Circuit accepts that framing, it could stall or reshape the litigation while the FDA completes its review; if it rejects it, the court would be deciding sensitive regulatory questions that historically belonged to the agency.

Standing and injury questions are equally central. Murrill advances state interests in enforcing Louisiana's abortion restrictions, while Markezich alleges she was coerced into taking abortion pills, a personal-injury claim that, if credited, gives the case a concrete plaintiff and distinguishes it from more abstract state-injury theories that have previously faltered. The panel's composition adds another layer: two of the three judges were nominated by Democratic presidents Barack Obama and Joe Biden, and one by Republican George W. Bush, a relatively moderate lineup for a circuit known as one of the most conservative in the country. Any panel decision, however, could be revisited en banc or appealed to the Supreme Court, where the ultimate fate of medication abortion regulation may be decided.

The political calendar amplifies the stakes. The arguments arrive in a 2026 midterm election year in which President Donald Trump's anti-abortion supporters are openly frustrated that the shield-law workaround persists, even as most voters say they favor legal abortion access in most cases. That divide means the litigation is likely to be leveraged as a campaign issue regardless of the legal outcome, and it raises the profile of the FDA's parallel regulatory review.